VDAC1 and cancer: The MFF–VDAC1 complex acts therefore as a novel regulator of mitochondrial cell death and appears a promising actionable therapeutic target in cancer, as demonstrated by the findings that an MFF peptidomimetic was well-tolerated and elicited anti-cancer activity in several preclinical models, including patient-derived xenografts, primary breast and lung adenocarcinoma organoids, and glioblastoma neurospheres [38].